Skip to main content
. 2023 Feb 15;9(7):eadf3700. doi: 10.1126/sciadv.adf3700

Fig. 1. Choice of target antigen in TCR-T cell therapy.

Fig. 1.

(A) Tumor-associated antigens (TAAs) are overexpressed in tumor versus normal tissues, whereas tumor-specific antigens (TSAs) are expressed exclusively in the tumor. Pros and cons of each antigen type are displayed in the last column. IHC, immunohistochemistry. (B) After identifying the antigen, epitopes need to be predicted on the basis of data-driven bioinformatic tools (examples: NetMHC and MHC Flurry) and their presence in tumor cells confirmed by peptidomics/immunopeptidomics. These steps are followed by the identification of epitope-specific TCRs. Int, intensity; m/z, mass/charge ratio.